Onvatilimab, referred to as JNJ-61610588, represents a novel clinical antibody directed towards {PD-1 | the PD-1 protein) and currently undergoing review for a range of {cancer | malignant diseases ) treatments. This engineered IgG4 specific antibody demonstrates considerable capability in inhibitin